使用法国临床数据对体模型研究的活力进行评估
Edouard Koch1, Marion Morel2, Nathalie Duchateau2
1Department of ophthalmology, Centre Hospitalier de Versailles, Versailles, 78000, France. ekoch@ght78sud.fr.
Scientific reports
|November 19, 2025
概括
在白内障手术后,AcrySof IQ Vivity托里克眼内镜 (IOL) 提供了良好的中间视力和折射结果. 这种 toroic 扩展焦点深度 IOL 显示出出色的旋转稳定性和患者满意度.
科学领域:
- 眼科医生 眼科 眼科
- 生物医学工程 生物医学工程
- 视光学测量 视光学测量 视光学测量
背景情况:
- 白内障手术通常需要眼内透镜 (IOL) 来纠正折射误差.
- 托里克内膜眼镜专门针对光,而扩展焦点深度 (EDOF) 的内膜眼镜则旨在改善多个距离的视力.
研究的目的:
- 为了评估AcrySof IQ Vivity眼镜的折射和视觉结果,扩展焦点深度 (EDOF) 的眼镜植入.
- 评估植入后三个月的旋转稳定性和患者满意度.
主要方法:
- 一项前性研究涉及27只眼睛,植入了AcrySof IQ Vivity托里克IOL.
- 三个月后对纠正的视敏度 (CDVA),距离纠正的中间视敏度 (DCIVA) 和未纠正的视敏度 (UDVA,UIVA,UNVA) 的评估.
- 测量眼镜旋转和评估患者报告的结果,包括眼镜独立性,光和光环.
主要成果:
- 单眼DCIVA的中位数为0.16 logMAR,与其他研究相比.
- 平均球体等价值为0.11 ± 0.31 D,其余的白是-0.42 ± 0.25 D.
- 平均IOL旋转为3.52±2.87度,其中86%的受试者显示旋转≤5°. 81%的人说他们很少需要眼镜来保持中等视力.
结论:
- 艾克瑞索夫IQ Vivity眼镜实现了有利的中间视力和折射效果.
- 植入物表现出良好的旋转稳定性,并有助于高患者满意度和眼镜独立.
- 结果与Vivity EDOF IOLs的先前研究相似,支持其在白内障手术中的有效性.
相关概念视频
Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Open Angle Glaucoma: Treatment
938
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
938
Clinical Trials
10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.1K
Glaucoma: Overview
1.2K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.2K
Angle Closure Glaucoma: Treatment
1.1K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.1K
Drug Product Performance: In Vitro–In Vivo Correlation
216
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
216


